{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T14:44:35Z","timestamp":1767105875268,"version":"3.48.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Ministry of Food and Drug Safety (MFDS), Republic of Korea","award":["22183 \uaddc\uc81c\ud559 368"],"award-info":[{"award-number":["22183 \uaddc\uc81c\ud559 368"]}]},{"name":"Ministry of Food and Drug Safety (MFDS), Republic of Korea","award":["22183 \uaddc\uc81c\ud559 368"],"award-info":[{"award-number":["22183 \uaddc\uc81c\ud559 368"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s43441-025-00870-3","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:33:09Z","timestamp":1760103189000},"page":"190-198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trends in FDA Data Integrity Enforcement Before and After the COVID-19 Pandemic: An Analysis of 1766 Warning Letters (2016\u20132023)"],"prefix":"10.1007","volume":"60","author":[{"given":"Yoseok","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyenghee","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"870_CR1","unstructured":"European Medicines Agency. Reflection paper on GMP\/GDP data integrity. EMA\/155013\/2021. London: EMA; 2021. Accessed June 20, 2025. https:\/\/www.ema.europa.eu."},{"issue":"10","key":"870_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.9734\/jpri\/2024\/v36i107585","volume":"36","author":"P Ullagaddi","year":"2024","unstructured":"Ullagaddi P, Sirohi R, Kumar A. FDA warning letter trends: a 15-year analysis. J Pharm Res Int. 2024;36(10):14\u201323. https:\/\/doi.org\/10.9734\/jpri\/2024\/v36i107585.","journal-title":"J Pharm Res Int"},{"key":"870_CR3","unstructured":"U.S. Food and Drug Administration. Warning letters database, 2016\u20132023. Silver Spring, MD: FDA. Accessed June 20, 2025. https:\/\/www.fda.gov\/inspections-compliance-enforcement-and-criminal-investigations\/warning-letters."},{"issue":"3","key":"870_CR4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.17480\/psk.2025.69.3.291","volume":"69","author":"Y Park","year":"2025","unstructured":"Park Y, Kwon K. Analysis of FDA data integrity violations before and after the COVID-19 pandemic: a warning letter-based comparative study. Yakhak Hoeji. 2025;69(3):291\u2013300. https:\/\/doi.org\/10.17480\/psk.2025.69.3.291.","journal-title":"Yakhak Hoeji"},{"key":"870_CR5","unstructured":"Pharmaceutical Inspection Co-operation Scheme (PIC\/S). PI 041-1: Good Practices for Data Management and Integrity in Regulated GMP\/GDP Environments. Geneva: PIC\/S; 2021. Accessed June 20, 2025. https:\/\/picscheme.org\/en\/publications."},{"key":"870_CR6","unstructured":"World Health Organization. Guidance on Good Data and Record Management Practices. WHO Technical Report Series No. 996, Annex 5. Geneva: WHO; 2016."},{"key":"870_CR7","unstructured":"Medicines and Healthcare products Regulatory Agency. GxP Data Integrity Guidance and Definitions. Revision 1. London: MHRA; March 2018. Accessed June 20, 2025. https:\/\/www.gov.uk\/government\/publications\/guidance-on-gxp-data-integrity."},{"key":"870_CR8","unstructured":"Pharmaceuticals and Medical Devices Agency. GMP Compliance Inspection Manual (English edition). Tokyo: PMDA; 2022. Accessed June 20, 2025. https:\/\/www.pmda.go.jp."},{"issue":"2","key":"870_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.5731\/pdajpst.2017.007765","volume":"72","author":"AK Rattan","year":"2018","unstructured":"Rattan AK. Data integrity: history, issues, and remediation of issues. PDA J Pharm Sci Technol. 2018;72(2):105\u201316. https:\/\/doi.org\/10.5731\/pdajpst.2017.007765.","journal-title":"PDA J Pharm Sci Technol"},{"issue":"2","key":"870_CR10","doi-asserted-by":"publisher","first-page":"416","DOI":"10.25258\/ijpqa.14.2.29","volume":"14","author":"M Tayade","year":"2023","unstructured":"Tayade M, Deshmukh M, Waghmare R, et al. Data integrity violations in the pharmaceutical industry and regulatory measures. Int J Pharm Qual Assur. 2023;14(2):416\u201320. https:\/\/doi.org\/10.25258\/ijpqa.14.2.29.","journal-title":"Int J Pharm Qual Assur"},{"issue":"4","key":"870_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.5639\/gabij.2020.0904.028","volume":"9","author":"SC Hock","year":"2020","unstructured":"Hock SC, Tay V, Sachdeva V, Wah CL. Pharmaceutical data integrity: issues, challenges and proposed solutions for manufacturers and inspectors. Gener Biosimilars Initiat J. 2020;9(4):171\u201383.","journal-title":"Gener Biosimilars Initiat J"},{"key":"870_CR12","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.15026723","author":"N Tripathi","year":"2023","unstructured":"Tripathi N, Kumar P. Data engineering for GxP compliance. 2023. Zenodo. https:\/\/doi.org\/10.5281\/zenodo.15026723."},{"issue":"8","key":"870_CR13","doi-asserted-by":"publisher","first-page":"2100060","DOI":"10.1002\/biot.20210060","volume":"16","author":"L Diomede","year":"2021","unstructured":"Diomede L, Mancini A, Monteleone G, et al. Data integrity within the biopharmaceutical sector in the era of Industry 4.0. Biotechnol J. 2021;16(8):2100060. https:\/\/doi.org\/10.1002\/biot.20210060.","journal-title":"Biotechnol J"},{"key":"870_CR14","unstructured":"U.S. Food and Drug Administration. Data Integrity and Compliance with CGMP: Guidance for Industry. FDA; 2016."},{"key":"870_CR15","unstructured":"International Council for Harmonisation. ICH Q9(R1): Quality Risk Management. Geneva: ICH; 2023. Accessed June 20, 2025. https:\/\/www.ich.org."}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-025-00870-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-025-00870-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-025-00870-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T14:40:09Z","timestamp":1767105609000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-025-00870-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["870"],"URL":"https:\/\/doi.org\/10.1007\/s43441-025-00870-3","relation":{"references":[{"id-type":"doi","id":"10.5281\/zenodo.15026723","asserted-by":"subject"}]},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"type":"print","value":"2168-4790"},{"type":"electronic","value":"2168-4804"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study did not involve human participants, personal data, or clinical interventions. Therefore, ethics approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}